We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,686 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.57 | 188.01B |
TIDMAZN
RNS Number : 7876A
AstraZeneca PLC
28 March 2017
28 March 2017 16:00 BST
TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announces that, on 28 March 2017, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) and of American Depositary Shares (ADSs) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent to one Ordinary Share.
The AZDBP award was granted on 28 March 2014, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2013 performance into Ordinary Shares or ADSs, and vested on completion of the three-year holding period.
The AZPSP award was granted on 28 March 2014. Following the application of performance measures specified at the time of grant, 92% of the AZPSP vested and the remaining unvested part immediately and irrevocably lapsed.
Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares and ADSs changed as detailed in the table below:
PDMR Ordinary ADSs acquired Ordinary ADSs acquired Shares under the Shares under the acquired AZDBP acquired AZPSP under the under the AZDBP AZPSP -------------- ----------- -------------- ----------- -------------- Pascal Soriot 14,209 101,584 -------------- ----------- -------------- ----------- -------------- Marc Dunoyer 1,419 25,478 -------------- ----------- -------------- ----------- -------------- Mark Mallon 620 22,000 -------------- ----------- -------------- ----------- --------------
For tax purposes, the fair market value of an Ordinary Share at vest was 4974.5 pence and the fair market value of an ADS at vest was $31.80, being the relevant closing prices on the last trading day preceding the vesting day.
Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Enquiries Esra Erkal-Paler UK/Global +44 203 749 5638 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Henry Wheeler Oncology +44 203 749 5797 Mitchell Chan Oncology +1 240 477 3771 Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Nick Stone Respiratory +44 203 749 5716 Christer Gruvris Autoimmunity, Neuroscience & Infection +44 203 749 5711 US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
1 Details of the person discharging managerial responsibilities / person closely associated --- --------------------------------------------------------------- a) Name Pascal Soriot --- ------------------------- ------------------------------------ 2 Reason for the notification --- --------------------------------------------------------------- a) Position/status Chief Executive Officer --- ------------------------- ------------------------------------ b) Initial notification Initial notification /Amendment --- ------------------------- ------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name AstraZeneca PLC --- ------------------------- ------------------------------------ b) LEI PY6ZZQWO2IZFZC3IOL08 --- ------------------------- ------------------------------------ 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description of Ordinary Shares of US$0.25 the financial each in AstraZeneca PLC instrument, type of instrument GB0009895292 Identification code --- ------------------------- ------------------------------------ b) Nature of the Acquisition of ordinary shares transaction pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. --- ------------------------- ------------------------------------ c) Price(s) and volume(s) Price(s) Volume(s) --------- ---------- 0 115,793 --------- ---------- --- ------------------------- ------------------------------------ d) Aggregated information Not applicable - single transaction - Aggregated volume - Price --- ------------------------- ------------------------------------ e) Date of the transaction 28 March 2017 --- ------------------------- ------------------------------------ f) Place of the transaction Outside a trading venue --- ------------------------- ------------------------------------ 1 Details of the person discharging managerial responsibilities / person closely associated --- --------------------------------------------------------------- a) Name Marc Dunoyer --- ------------------------- ------------------------------------ 2 Reason for the notification --- --------------------------------------------------------------- a) Position/status Chief Financial Officer --- ------------------------- ------------------------------------ b) Initial notification Initial notification /Amendment --- ------------------------- ------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name AstraZeneca PLC --- ------------------------- ------------------------------------ b) LEI PY6ZZQWO2IZFZC3IOL08 --- ------------------------- ------------------------------------ 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description of Ordinary Shares of US$0.25 the financial each in AstraZeneca PLC instrument, type of instrument GB0009895292 Identification code --- ------------------------- ------------------------------------ b) Nature of the Acquisition of ordinary shares transaction pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. --- ------------------------- ------------------------------------ c) Price(s) and volume(s) Price(s) Volume(s) --------- ---------- 0 26,897 --------- ---------- --- ------------------------- ------------------------------------ d) Aggregated information Not applicable - single transaction - Aggregated volume - Price --- ------------------------- ------------------------------------ e) Date of the transaction 28 March 2017 --- ------------------------- ------------------------------------ f) Place of the transaction Outside a trading venue
--- ------------------------- ------------------------------------ 1 Details of the person discharging managerial responsibilities / person closely associated --- --------------------------------------------------------------- a) Name Mark Mallon --- ------------------------- ------------------------------------ 2 Reason for the notification --- --------------------------------------------------------------- a) Position/status Person Discharging Managerial Responsibilities --- ------------------------- ------------------------------------ b) Initial notification Initial notification /Amendment --- ------------------------- ------------------------------------ 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- --------------------------------------------------------------- a) Name AstraZeneca PLC --- ------------------------- ------------------------------------ b) LEI PY6ZZQWO2IZFZC3IOL08 --- ------------------------- ------------------------------------ 4i Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- --------------------------------------------------------------- a) Description of AstraZeneca PLC American the financial Depositary Shares instrument, type of instrument CUSIP: 046353108 Identification code --- ------------------------- ------------------------------------ b) Nature of the Acquisition of ADSs pursuant transaction to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration. --- ------------------------- ------------------------------------ c) Price(s) and volume(s) Price(s) Volume(s) --------- ---------- 0 22,620 --------- ---------- --- ------------------------- ------------------------------------ d) Aggregated information Not applicable - single transaction - Aggregated volume - Price --- ------------------------- ------------------------------------ e) Date of the transaction 28 March 2017 --- ------------------------- ------------------------------------ f) Place of the transaction Outside a trading venue --- ------------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUWSORBNAOUAR
(END) Dow Jones Newswires
March 28, 2017 11:00 ET (15:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions